MPLT - MapLight Therapeutics, Inc. Stock Analysis

Stock Taper

SCREENER COMPARE ANY 2 STOCKS

MPLT

MAPLIGHT THERAPEUTICS, INC.

NASDAQ

$12.60

▲ UP 0.48% (0.06)

KEY STATISTICS

Market Cap$534.70 M

52w High$40.43

52w Low$9.10

Dividend Yield—

Frequency—

P/E-0.33

Volume375.07K

Shares Out.42.44M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Christopher A. Kroeger

COMPENSATION 2026

Salary$655,250

Stock Awards$12,296,267

Incentive Plan Pay$331,000

All Other Comp.$19,331

Total$25,624,254

ABOUT

SECTOR

Healthcare

WENT PUBLIC

October 24, 2025

METHOD OF GOING PUBLIC

SPAC

FULL TIME EMPLOYEES

133

PRICE TARGET

Target High$46.00

Target Low$13.00

Target Median$28.00

Target Consensus$29.40

UPCOMING EARNINGS

DateSep 18, 2026

DayFriday

Rev. Est.—

SEP

FRI

PRICE

$12.60 ▲ UP 0.48% (+$0.06)

About MapLight Therapeutics, Inc.

https://www.maplightrx.com ↗

MapLight Therapeutics, Inc., a Redwood City-based biopharma company, develops CNS disorder treatments like ML-007C-MA and ML-004, and targets neural circuits for therapeutic modulation.

INDUSTRY

Biotechnology

A PRODUCT MAPLIGHT THERAPEUTICS, INC. IS KNOWN FOR

ML-007C-MA

ML-007C-MA is a Phase 2 investigational oral medication by MapLight targeting M1 and M4 receptors to treat schizophrenia and Alzheimer's psychosis with a focused approach to improve symptoms and reduce side effects.